Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, SINGLE-ARM PROSPECTIVE STUDY TO EVALUATE SAFETY AND EFFICACY OF GLE/PIB 8-WEEK TREATMENT IN ADULTS AND ADOLESCENTS WITH ACUTE HEPATITIS C VIRUS (HCV) INFECTION

Intervention/treatment:
GLECAPREVIR (ABT-493)-PIBRENTASVIR (ABT-530)
Medical condition:
HEPATITIS C VIRUS
Protocol code:
M20-350
Control number:
251257
Status:
Closed
Approved:
July 15, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04903626
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

British Columbia

CoolAid Medical Clinic /ID# 239978
Victoria, British Columbia, V8W 1M8
Vancouver Infectious Diseases Centre /ID# 227125
Vancouver, British Columbia, V6Z 2C7

Ontario

Charlton Medical Centre /ID# 228100
Hamilton, Ontario, L8N 1Y2

Quebec

Royal Victoria Hospital / McGill University Health Centre /ID# 227126
Montreal, Quebec, H4A 3J1

Results

See the results from the trial NCT04903626. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?